查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472312

肺氣腫治療市場：依治療類型、類型、最終用戶：2023-2032 年全球機會分析與產業預測

Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 310 Pages | 商品交期: 2-3個工作天內

價格

2022年全球肺氣腫治療市值為63億美元，預計2023年至2032年複合年成長率為3.3%，到2032年達到87億美元。

肺氣腫是一種慢性疾病，其特徵是肺部氣囊（肺泡）受損，導致呼吸困難。這種損害是由於長期暴露於刺激物，尤其是香菸煙霧造成的。當脆弱的氣囊壁受損時，它們會失去彈性，使肺部難以正常呼氣。結果，空氣滯留在肺部並導致肺部腫脹，導致呼吸短促、咳嗽、喘息和其他呼吸道症狀。肺氣腫的治療主要集中在控制症狀和防止肺部進一步受損。通常會使用支氣管擴張劑等藥物來放鬆氣道周圍的肌肉並改善氣流。在嚴重的情況下，皮質類固醇用於減輕肺部發炎。如果血氧水平低，可能需要氧氣療法。隨著疾病的進展，因肺氣腫引起嚴重呼吸問題的患者可能會考慮接受手術選擇，例如肺減容手術或肺移植。

肺氣腫治療市場-IMG1

全球肺氣腫治療市場的成長預計將受到肺氣腫盛行率上升和全球吸菸者數量迅速增加的推動。由於老年人口的迅速成長、環境污染的驚人增加以及全球吸煙率的不斷上升，肺氣腫在世界各地變得越來越普遍。例如，根據美國國家醫學圖書館2022年發表的一篇論文，美國肺氣腫盛行率約1,400萬人，是美國最主要的慢性阻塞性肺病。

此外，空氣污染、工業排放和接觸有害顆粒物等環境因素會增加肺氣腫的風險，尤其是在污染程度較高的都市區。全球肺氣腫發病率的上升導致管理這種慢性疾病的有效治療性介入激增，預計這將促進全球肺氣腫治療市場的成長。

此外，全球吸菸者數量的增加已成為肺氣腫治療市場的關鍵驅動力。例如，根據世界衛生組織（WHO）2021年版的數據，全球22.3%的人口使用菸草，130萬吸菸者居住在低收入和中等收入國家。隨著世界各地吸菸人數的增加，肺氣腫的發生率也增加。吸煙被廣泛認為是發生肺氣腫的主要危險因素，因為它會加速肺功能的惡化並加劇現有的呼吸道疾病。因此，吸菸者數量的增加導致對有效治療的需求增加，以控制與肺氣腫相關的症狀並改善患者的生活品質。因此，全球吸菸者數量的增加預計將推動市場成長。

全球肺氣腫治療市場按治療類型、類型、最終用戶和地區細分。依治療類型分類，市場分為藥物治療、氧氣療法和手術。依類型分為中心性、泛性等。依最終用戶分類，可分為醫院、居家醫療、專科中心等。按地區分類，北美（美國、加拿大、墨西哥）、歐洲（法國、德國、義大利、英國等歐洲地區）、亞太地區（中國、日本、印度、韓國） 、澳洲和其他亞太地區），分析了南美地區（巴西、非洲、阿拉伯和亞太其他地區）。

相關人員的主要利益

  • 該報告對 2022 年至 2032 年肺氣腫治療市場分析的細分市場、當前趨勢、估計和動態進行了定量分析，並確定了肺氣腫治療市場的強大機會。
  • 它提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 對肺氣腫治療市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與企業定位有助於基準化分析並描述對市場參與企業當前地位的清晰了解。
  • 它包括區域和全球肺氣腫治療市場趨勢、主要企業、細分市場、應用細分、市場成長策略等的分析。

可以使用此報告進行報告客製化（可能需要額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 肺氣腫患者增加
      • 全球吸菸者人數迅速增加
      • 空氣污染加劇導致肺氣腫
    • 抑制因素
      • 昂貴的治療費用
      • 與藥物相關的副作用
    • 機會
      • 新興市場的成長機會

第4章肺氣腫治療市場：依治療類型

  • 概述
  • 藥物治療
    • 藥物治療肺氣腫治療市場：依類型
  • 氧氣療法
  • 手術治療

第5章肺氣腫治療市場：依類型

  • 概述
  • 中心體
  • 帕納西納爾
  • 其他

第6章肺氣腫治療市場：依最終使用者分類

  • 概述
  • 醫院
  • 居家醫療
  • 專業中心
  • 其他

第7章肺氣腫治療市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc.
  • Viatris Inc.
  • Novartis AG
  • Orion Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma Plc.
  • Koninklijke Philips NV
  • Inogen, Inc.
Product Code: A14372

The global emphysema treatment market was valued at $6.3 billion in 2022, and is projected to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Emphysema is a chronic condition characterized by damage to the air sacs (alveoli) in the lungs, leading to difficulty in breathing. This damage is caused by long-term exposure to irritants, most commonly cigarette smoke. When the delicate walls of the air sacs are damaged, they lose their elasticity, making it difficult for the lungs to exhale properly. As a result, air is trapped in the lungs, causing them to inflate and leading to shortness of breath, coughing, wheezing, and other respiratory symptoms. Treatment for emphysema focuses primarily on managing symptoms and preventing further lung damage. Medications such as bronchodilators, which help to relax the muscles around the airways and improve airflow, are commonly prescribed. In more severe cases, corticosteroids are used to reduce inflammation in the lungs. Oxygen therapy may be necessary for those with low blood oxygen levels. In advanced stages, surgical options like lung volume reduction surgery or lung transplantation is considered for patients with severe breathing issues due to emphysema .

Emphysema Treatment Market - IMG1

The growth of the global emphysema treatment market is expected to be driven by rise in incidence of emphysema and surge in number of smokers globally. Emphysema has been increasingly prevalent across the globe due to surge in geriatric population, alarming rise in environmental pollution, and increase in prevalence of smoking worldwide. For instance, according to 2022 article published by the National Library of Medicine, the prevalence of emphysema in the U.S. is approximately 14 million and is leading COPD disorder across the U.S.

In addition, environmental factors such as air pollution, industrial emissions, and exposure to harmful particulate matter have escalated the risk of developing emphysema, especially in urban areas where pollution levels tend to be higher. The rise in incidence of emphysema globally has resulted in surge in effective therapeutic interventions to manage this chronic disease, which is expected to boost the growth of the global emphysema treatment market.

Furthermore, increase in the number of smokers globally has emerged as a key driving force of the emphysema treatment market. For instance, according to the World Health Organization (WHO) 2021, 22.3% world's population use tobacco with 1.3 million tobacco smokers residing in low- and middle-income countries. With increasing number of individuals adopting smoking habits worldwide, the incidence of emphysema has escalated simultaneously. Smoking is widely recognized as the primary risk factor for developing emphysema, as it leads to the progressive deterioration of lung function and exacerbates existing respiratory conditions. Consequently, the escalating number of smokers has contributed to a heightened demand for effective treatments to manage emphysema-related symptoms and improve patients' quality of life. Thus, rise in number of smokers globally is expected to drive the growth of the market.

The global emphysema treatment market is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy, and surgery. Depending on type, it is segregated into centriacinar, panacinar, and others. On the basis of end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Viatris Inc., Inogen, Teva Pharmaceuticals, Koninklijke Philips N.V., and Verona Pharma.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2022 to 2032 to identify the prevailing emphysema treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By End User

  • Hospitals
  • Homecare
  • Specialty Centres
  • Others

By Treatment Type

  • Medication
    • Type
    • Bronchodilators
    • Steroids
    • Others
  • Oxygen Therapy
  • Surgery

By Type

  • Centriacinar
  • Panacinar
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Viatris Inc.
    • Koninklijke Philips N.V.
    • GlaxoSmithKline Plc.
    • AstraZeneca
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Inogen, Inc.
    • Orion Corporation
    • Verona Pharma Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of emphysema cases.
      • 3.4.1.2. Surge in number of smokers globally.
      • 3.4.1.3. Increase in air pollution contributing to emphysema.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of treatment.
      • 3.4.2.2. Side effects associated with medications.
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets.

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Medication
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Medication Emphysema Treatment Market by Type
  • 4.3. Oxygen Therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Surgery
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Centriacinar
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Panacinar
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Homecare
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Specialty Centres
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Treatment Type
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Treatment Type
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Treatment Type
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Treatment Type
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Treatment Type
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Treatment Type
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Treatment Type
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Treatment Type
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Treatment Type
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Treatment Type
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Treatment Type
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Treatment Type
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Treatment Type
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Treatment Type
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Treatment Type
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Treatment Type
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Treatment Type
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Treatment Type
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Treatment Type
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Treatment Type
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Treatment Type
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Treatment Type
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Treatment Type
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. AstraZeneca
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Boehringer Ingelheim International GmbH
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. GlaxoSmithKline Plc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Viatris Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Orion Corporation
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Teva Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Verona Pharma Plc.
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Koninklijke Philips N.V.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Inogen, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. EMPHYSEMA TREATMENT MARKET FOR MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL MEDICATION EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. EMPHYSEMA TREATMENT MARKET FOR OXYGEN THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. EMPHYSEMA TREATMENT MARKET FOR SURGERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 07. EMPHYSEMA TREATMENT MARKET FOR CENTRIACINAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. EMPHYSEMA TREATMENT MARKET FOR PANACINAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 11. EMPHYSEMA TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. EMPHYSEMA TREATMENT MARKET FOR HOMECARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EMPHYSEMA TREATMENT MARKET FOR SPECIALTY CENTRES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. EMPHYSEMA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. CANADA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. UK EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. UK EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ITALY EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. CHINA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. INDIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 90. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 91. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 92. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 93. ASTRAZENECA: KEY STRATERGIES
  • TABLE 94. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 95. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 96. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 97. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 98. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 99. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 100. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
  • TABLE 101. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 102. GLAXOSMITHKLINE PLC.: KEY STRATERGIES
  • TABLE 103. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 104. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 105. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 107. VIATRIS INC.: KEY STRATERGIES
  • TABLE 108. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 110. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 112. ORION CORPORATION: KEY EXECUTIVES
  • TABLE 113. ORION CORPORATION: COMPANY SNAPSHOT
  • TABLE 114. ORION CORPORATION: PRODUCT SEGMENTS
  • TABLE 115. ORION CORPORATION: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 121. VERONA PHARMA PLC.: KEY EXECUTIVES
  • TABLE 122. VERONA PHARMA PLC.: COMPANY SNAPSHOT
  • TABLE 123. VERONA PHARMA PLC.: PRODUCT SEGMENTS
  • TABLE 124. VERONA PHARMA PLC.: PRODUCT PORTFOLIO
  • TABLE 125. VERONA PHARMA PLC.: KEY STRATERGIES
  • TABLE 126. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 127. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 128. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
  • TABLE 129. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 130. INOGEN, INC.: KEY EXECUTIVES
  • TABLE 131. INOGEN, INC.: COMPANY SNAPSHOT
  • TABLE 132. INOGEN, INC.: PRODUCT SEGMENTS
  • TABLE 133. INOGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 134. INOGEN, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. EMPHYSEMA TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF EMPHYSEMA TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN EMPHYSEMA TREATMENT MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN EMPHYSEMA TREATMENT MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR MEDICATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OXYGEN THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR SURGERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR CENTRIACINAR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR PANACINAR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. EMPHYSEMA TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR HOMECARE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR SPECIALTY CENTRES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. EMPHYSEMA TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 25. U.S. EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. CANADA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. MEXICO EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. GERMANY EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. FRANCE EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. UK EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. ITALY EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. SPAIN EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. JAPAN EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. CHINA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. INDIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. AUSTRALIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. BRAZIL EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
  • FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48. COMPETITIVE DASHBOARD
  • FIGURE 49. COMPETITIVE HEATMAP: EMPHYSEMA TREATMENT MARKET
  • FIGURE 50. TOP PLAYER POSITIONING, 2022
  • FIGURE 51. ASTRAZENECA: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 52. ASTRAZENECA: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. GLAXOSMITHKLINE PLC.: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 57. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 58. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 59. VIATRIS INC.: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 60. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 61. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 63. ORION CORPORATION: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 64. ORION CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 67. VERONA PHARMA PLC.: NET SALES, 2021-2022 ($MILLION)
  • FIGURE 68. KONINKLIJKE PHILIPS N.V.: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 69. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 70. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 71. INOGEN, INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 72. INOGEN, INC.: REVENUE SHARE BY REGION, 2023 (%)